BY & LARGE PEPTIDES

GIP / GLP-1 RECEPTOR AGONIST

Tirzepatide 40mg



Tirzepatide · 40mg vial

RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY CONSUMPTION · NOT FOR SELF-ADMINISTRATION

Tirzepatide is a 39-amino-acid peptide that activates both GIP and GLP-1 receptors. It is the active ingredient in specific prescription products; indications vary by product and country.

PRICING · PER VIAL

Mix & match any vials — 2–4 −10%, 5+ −15%

RETAIL 1 VIAL	2–4 −10%	5+ −15%
R902	R812	R767

HOW IT WORKS

Dual incretin activity supports glucose-dependent insulin signalling and affects appetite and food intake. A fatty-acid side chain extends its action in approved formulations.

RESEARCH CONTEXT

The FDA prescribing information for Mounjaro applies to its named, approved presentations. It should not be treated as interchangeable with an unbranded lyophilised vial.

VIAL CONTENTS & HANDLING

- 40mg tirzepatide
- Single lyophilised vial

Quality & sourcing. Sourced from established manufacturers who test using HPLC analysis. COA available on request — **ask us on WhatsApp ↗**

Storage: keep unopened lyophilised vials in a cool, dark place. Once reconstituted, store in the fridge at 2–8°C and use within 2 months.

RESEARCH REFERENCE DOSAGE

40mg vial · 3ml water · 13.33mg/ml

LEVEL	AMOUNT	U100 UNITS	FREQUENCY
Beginner	2.5mg	**18.75 units**	Once weekly or split 2× weekly · any time
Intermediate	5–7.5mg	**37.5–56.25 units**	Once weekly or split 2× weekly · any time
Advanced	10–15mg	**75–112.5 units**	Once weekly or split 2× weekly · any time

Fixed 3ml · U100 device (1 unit = 0.01ml). For split weekly schedules, use half the listed full-amount units per administration. Research reference only—not human-use guidance.

Dosing status: Approved products require their own prescribing information and clinical oversight. This table is a research reference only, not a conversion into guidance for human use.

REFERENCES

- FDA — Mounjaro (tirzepatide) Prescribing Information